Wendy Guy - 01 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Administrative Officer
Signature: /s/ Wendy Guy by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 01 Jan 2024
Net transactions value: -$1,027
Form type: 4
Filing time: 12 Apr 2024, 16:50:41 UTC
Previous filing: 12 Oct 2023
Next filing: 02 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Options Exercise		+1,675	+17%		11,801	01 Jan 2024	Direct	F1, F2
transaction	PCSA	Common Stock	Tax liability	$1,027	-368	-3.1%	$2.79	11,433	01 Jan 2024	Direct	F2
holding	PCSA	Common Stock						8,335	01 Jan 2024	By CorLyst, LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock Units	Options Exercise	$0	-1,675	-7.7%	$0.000000	20,132	01 Jan 2024	Common Stock	1,675	$0.000000	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Distribution of vested restricted shares.
F2	Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.